Abstract
Introduction
When a recurrence of lung cancer is suspected, re-biopsy is recommended for confirmation of recurrence and the histologic subtype for the selection of appropriate treatment. Moreover, with the development of targeted agents, tissue acquisition for biomarker studies including epidermal growth factor receptor (EGFR) mutation analysis becomes one of the foremost important reason for re-biopsy in patients with advanced lung cancer. According to the ESMO (European Society for Medical Oncology) guidelines, rebiopsy should be considered for the progressive disease, especially after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) [1] .
In the majority of the cases, the parenchymal lesion or a mediastinal lymph node is the target for re-biopsy, though it is also performed at various distant metastatic sites [2] . The re-biopsy is often considered technically difficult and is usually accompanied by higher rates of complication than the first biopsy [2] . Computed tomography (CT)-guided trans-thoracic needle biopsy (TTNB) is also widely used for both diagnosis and acquisition of tissue samples for biomarker studies, but it has rather higher risk of complications. The procedurerelated complication rates were found to be 14% in two studies which investigated the yield of image-guided lung re-biopsy, though the technical success rate of more than 80% was reported for mutational analysis [3, 4] .
For the purpose of mutational analysis, the tissue was acquired by the bronchoscopic method. Though there was no mention of the exact diagnostic yield of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA), 25% of 43 cases had inadequate specimen in one study [5] . In another study which utilized various procedures other than EBUS-TBNA, adequate tissue samples were available for EGFR analysis in only 34 out of 75 cases (45%) [6] . On the other hand, EBUS-TBNA yielded 100% adequacy of Korean Cancer Association This article is protected by copyright. All rights reserved.
tissue procurement for mutational analysis in two small series of nine and 18 patients who had disease progression after EGFR-TKI treatment [7, 8] .
EBUS-TBNA is used for the diagnosis and staging of lung cancer and has been shown to have a high diagnostic value with low rates of complications [9] . In addition, it was adequate for acquisition of tissue samples for EGFR mutation analysis, which was possible in 90%-95% of the non-small-cell lung carcinoma (NSCLC) patients at the time of initial diagnosis [10, 11] . EBUS-TBNA can also be used for histologic confirmation when recurrence is suspected. The sensitivity ranged from 80.9% to 100%, and the accuracy ranged from 86.6% to 100% in three studies evaluating the re-biopsy yields in patients with suspected recurrence after complete surgical resection [12] [13] [14] . There have been a few studies on re-biopsy for mutation analysis after tyrosine kinase inhibitor (TKI) and most studies included a small number of patients who were previously treated with either surgery or chemotherapy [7, 8] . The aim of our study is to evaluate the role of EBUS-TBNA for rebiopsy and to determine its adequacy for mutational analysis in lung cancer patients who have received previous treatments. We also compared the yield from EBUS-TBNA depending on the major treatment modality given previously.
Materials and Methods

Patients
This retrospective cohort study included patients who underwent EBUS-TBNA for the re-biopsy of recurrent or suspected progressive lesions after initial treatment, either EBUS-TBNA was performed for the purpose of staging or re-staging.
The diagnostic yield was calculated in two ways, according to prior treatment and the purpose of re-biopsy. First, we grouped the patients into three subgroups based on the previous treatment modality. The surgical group included patients who underwent surgery alone and those who underwent preoperative neoadjuvant therapy or postoperative adjuvant therapy. If radiation, concurrent chemoradiation therapy (CCRT) or chemotherapy was performed for recurred lesion after surgical treatment, it was classified as radiation or chemotherapy group. The radiation group included patients who received radiation or CCRT with curative intent for NSCLC stage I, II, III and small-cell lung carcinoma (SCLC) limited disease. The chemotherapy group included patients who received chemotherapy for palliation in the advanced stage NSCLC and SCLC extensive disease. Second, the purpose of re-biopsy was classified according to whether it was performed on a suspicious recurrent lesion in a patient who received prior treatment for curative purposes in localized lung cancer (curative group) or for tissue acquisition from progressive lesions after palliative therapy in an advanced stage (palliative group).
Procedure
EBUS-TBNA was performed using an ultrasound bronchoscope and a dedicated ultrasound processor (convex probe-EBUS, BF-UC260F-OL8 and EU-C2000, Olympus, Tokyo, Japan). Needle aspiration was performed with a 22-gauge needle (NA-201SX-4022; Olympus). Transesophageal endoscopic ultrasound with bronchoscope-guided fine-needle aspiration was also used additively for mediastinal lymph node aspiration in cases that were difficult to approach with EBUS.
The number of aspirations, core tissues obtained and reasons for performing EBUS Korean Cancer Association
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was also extracted from the bronchoscopy reports. The number of aspirations was determined from the number of times the target lesion was needled. The tissue core was defined gross tissue was obtained by TBNA.
Results and diagnostic yield
The biopsy specimens were reviewed by a pathologist. The results were classified as true positive, true negative, false-negative or not applicable. A case in which cancer was confirmed in the pathology report was defined as true positive. Otherwise, whether a case was a true negative or false-negative after a minimum of 6 months of follow-up. The true negative was defined as the case which was surgically confirmed or the case who had no evidence of disease progression. The false negative was defined as a case in which cancer was confirmed by other diagnostic methods, or there was progression within 6 months. Cases of patients who were lost to follow-up before 6 months were classified as 'Not-applicable'
cases. Not-applicable cases were excluded from the calculation of prevalence, sensitivity, negative predictive value and accuracy, but included for calculation of prevalence. Adequacy was judged based on the pathology report. The reports with "insufficient specimen, mainly blood, no tissue, cartilage and not available for diagnosis" were classified as inadequate.
Though mutation analysis was performed on the clinician's request, actual processing was done only in specimens with an adequate amount of good quality tissue.
Data collection
Demographic and clinical data, as well as information on initial diagnosis, pathology, cancer stage and previous treatment history was reviewed and recorded. The radiotherapy planning was also reviewed to determine if the target lesion was located inside or outside the 8
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previous radiation field by 20 Gy as a reference.
We reviewed chest CT and positron emission tomography computed tomography (PET-CT) images which were obtained within one month of the re-biopsy, for measurement of the aspirated target size and standardized uptake value (SUV). The short-axis diameters of the lymph node and long-axis diameters of the lung parenchymal lesion were measured on the axial section of the chest CT. The maximum SUV of the target lesion was measured by a nuclear medicine specialist.
Reasons for performing EBUS, instead of other biopsy methods such as transthoracic needle aspiration or biopsy (TTNA or TTNB) were classified into (1) the mediastinal lymph node was the main target, (2) the parenchymal lesion was the main target which was accessible by EBUS, (3) EBUS-TBNA was performed at another site rather than the main target which is the inaccessible parenchymal lesion and (4) though there was a visible endobronchial lesion, bronchoscopic biopsy was difficult due to bleeding or acute angulation of bronchus.
Ethical statement
This study was approved by the National Cancer Center Institutional Review Board (IRB no. NCC2016-0257) and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived. Table 1 . In most cases (330 cases, 88.9%), the mediastinal lymph nodes or parenchymal lesions, which were suspected to be recurrence or progression, were the main target lesions approachable by EBUS. In 22 patients (5.9%), the main target lesion could not be accessed with EBUS and was difficult to access by TTNA as well, because of the difficulty of discriminating malignant portions of the lesions from the surrounding malignant effusion. In those cases, EBUS-TBNA was performed for in alternative lesions with low malignant potential. Of the patients who used TKI, sampling was done in relatively stable lesions rather than in definite progressive lesions in five patients. The remaining 19 cases (5.1%) had endobronchial lesions which were accessible but were either difficult to biopsy or bleed easily.
Among the 548 target lesions which were aspirated, lymph nodes accounted for 78.7%, while the remaining were bronchial stump/peribronchial soft tissue (3.4%), lung parenchymal lesion (17.6%) and pleural lesion (0.2%) ( Table 2 ). Mean size of the aspirated lymph node was 11.4 ±4.6 mm and mean size of the non-nodal lesion, such as parenchymal, stump or peribronchial lesions, was 33.5 ±20.8 mm. The mean value of maximum SUV of the aspirated target was 6.6±4.4 in 290 patients with PET-CT. The needle aspiration via EBUS was performed 3.4 times, and on average, tissue core was obtained 2.7 times.
In 33 patients, biopsies were repeated more than twice: 4 times in five patients, 3 times in nine patients and twice in 19 patients. The result of the first re-biopsy was used in the analysis of yield. All cases were performed for the purpose of mutational analysis, rather Korean Cancer Association This article is protected by copyright. All rights reserved.
than because the sample was inadequate.
The average time taken to perform EBUS-TBNA was 25.8±10.2 minutes. Post procedure complications were observed in 12 patients. Six patients experienced desaturation during the procedures but recovered immediately after increasing the inhaled oxygen flow.
Three patients developed a transient fever within 48 hours of the procedure, and bleeding occurred in two patients during the procedure. One patient had chest pain after the procedure with no evidence of a cardiogenic problem. There were no such major complications, as pneumomediastinum, mediastinitis or severe bleeding that required intervention.
Diagnostic yield of EBUS-TBNA
The tumor was detected by EBUS-TBNA in 283 patients (76.3%) ( Table 3) . Among 88 patients (23.7%) with negative results, median follow-up duration was 28.4 months (quartile 17.2 to 52.2 months), and 61 patients (69.3%) had been followed up more than 1 year. Twelve patients (3.2%) were classified as not applicable with follow-up of less than 6 months. After excluding these 12 patients, the diagnostic yield had a sensitivity of 95.6%, the negative predictive value of 82.9%, and diagnostic accuracy of 96.4%. Among the 13 falsenegative cases, nine had targeted a lymph node or lung parenchyma as the main lesion, and four of them aspirated a lymph node instead of an untargetable parenchymal or pleural lesion.
The overall adequacy was 94.7%, and proportion of inadequate specimen was higher in the non-nodal targets (n=15, 12.8%) than in the nodal targets (n=14, 3.2%) (S1 Table) .
The sensitivity, NPV, and accuracy were higher than 90% in the surgical group. The subgroup which previously underwent surgery alone showed the highest diagnostic yield, while the group that underwent surgery after neoadjuvant therapy showed the lowest, although difference was not statistically significant. The overall sensitivity (87.8%) and Korean Cancer Association This article is protected by copyright. All rights reserved.
accuracy (90.7%) was low in the radiation group, regardless of being combined with chemotherapy. The NPV was 60.0% in the chemotherapy group, but the diagnostic accuracy and sensitivity were both 98%. The prevalence in the chemotherapy group (97.5%) was higher than in the surgical group (74.7%) or radiation group (75.9%). The sensitivity, NPV and accuracy were significantly different among the three groups (p=0.007, p=0.042, p=0.042, respectively). The radiation group had a significantly lower diagnostic yield when compared to the other two groups, while the surgical and chemotherapy therapy groups had comparable yields. The adequacy of each target was also significantly lower in the radiation group (83.7%) compared to that in the surgical (95.4%) or chemotherapy groups (97.5%, p< 0.001).
When classified according to the purpose of re-biopsy, the prevalence was as low as 73.1% and the NPV was 85.7% in the curative group. The sensitivity and accuracy were 93.9% and 95.5%, respectively. In the palliative group, prevalence was as high as 97.7% and NPV was 50%. The sensitivity and accuracy were both as high as 98%, similar to those in the curative group. The average number of examined lymph nodes, aspirations and core tissue samples were similar between the two groups. Sixty-one patients, who received radiation therapy in surgery and radiation group, showed a high sensitivity of 90% and accuracy of 90%. Inadequate specimens were collected from 12 of the 86 target lesions (13.9%), and 9 of them were located inside the previously radiated field. There were five false-negative cases, of which three had inadequate specimens.
Pathology, mutation analysis and treatment decision
Among the 283 patients who were found to have a malignancy at re-biopsy, 23
(6.2%) had a pathology different from the initial diagnosis. Among them, 19 patients, who Korean Cancer Association This article is protected by copyright. All rights reserved.
were suspected to have recurrence or progression of pre-existing cancer, but were found to have a new tumor on re-biopsy (Table 4) .
At the time of re-biopsy, EGFR or anaplastic lymphoma kinase (ALK) mutation analysis was requested in 105 (37.1%) of 283 patients. It has been requested since 2010, which was initially performed only in 10% of the case with malignancy confirmed but steadily increased to more than 50% in 2016.
Among 105 patients, five patients were excluded because of inadequate specimens, and the analysis was performed in 100 patients (95.2%); 87 patients for EGFR, 52 patients for ALK. EGFR mutation was detected in 49 (56.3%) of 87 patients while ALK mutation was found in four of 52 patients (7.7%). Among these 49 patients, 39 (79.6%) had previously used TKI and 10 (25.6%) acquired the T790M mutation.
The treatment plan was determined based on the results of the re-biopsy (Table 5) .
Among the 283 cases with recurrent or progressive disease confirmed, most patients (87.3%)
were switched to other treatment methods or new regimens of chemotherapy. No treatment decision for change was rendered for 36 patients (12.7%), either due to poor performance status or the patient's decision to stop further treatment. Among 88 patients with negative results, 66 (75%) were further followed up with imaging. A biopsy was repeated for suspicious lesions in six patients, which was then confirmed as true-negative in two patients and false-negative in four patients. Korean Cancer Association This article is protected by copyright. All rights reserved.
Discussion
With recent development of targeted therapy for lung cancer, the need for re-biopsy for biomarker studies is increasing to find out whether targeted therapy is indicated and also to identify intrinsic or acquired resistance in patients previously treated with targeted therapy.
It is also important for the enrollment of patients to the clinical study. We investigated the yield of EBUS-TBNA when it was performed to diagnose recurrence or disease progression in patients who underwent variety of treatment previously. In contrast to previous studies which included patients who received only one kind of treatment [12-14], we included patients who had undergone surgical resection, radiation, and chemotherapy, either as alone or in combinations.
In our study of 371 patients with lesions suspected recurrent or progressing lesions, EBUS-TBNA revealed a high overall accuracy and sensitivity of greater than 90%.
Sensitivity and accuracy were especially high in the surgical and chemotherapy groups, approaching 96%-98%. NPV was low in the chemotherapy group due to low prevalence of negative EBUS-TBNA results, mainly because EBUS-TBNA was performed for tissue acquisition of the progressive lesions following prior treatment in most cases.
Surgery group accounts for the majority of the recurrent lesions in our study. After surgery, anatomical changes, such as obstruction, narrowing or distortion, occur inevitably after lung resection in this group [15, 16] (Fig. 1A) . In addition, pulmonary toxicity is one of the well-known adverse effects of chemotherapy and radiation therapy. The histological analysis shows inflammation, fibrosis, collagenization, and elastosis as well as necrosis and nuclear shrinkage of tumor cells after chemotherapy [17, 18] (Fig. 1B) . Normal cells are also affected similarly [19] . Complications are related not with just conventional chemotherapeutic agents, but also with targeted anticancer agents [20] . Radiation therapy Korean Cancer Association This article is protected by copyright. All rights reserved.
also induces damage to cells, such as alveolar congestion, inflammation or fibrosis and causes more aggressive and irreversible structural changes [21, 22] (Fig. 1C) . These changes could occur outside of the radiation field, or even on the contralateral side, thereby affecting the whole lung [23, 24] .
However, EBUS-TBNA showed good diagnostic yield regardless of previous treatment, though various treatment-related tissue damages make the biopsy procedure difficult. The yield for re-biopsy was excellent in the chemotherapy group, better than that in the other treatment groups. It may be because after chemotherapy, the structural changes are relatively less severe than surgery or radiation. Though sensitivity, accuracy, and adequacy were significantly lower in the radiation group than in the other groups, the overall diagnostic yield was acceptable with high accuracy. There has been no study evaluating the yield of EBUS-TBNA after radiation therapy, but our findings suggest that it should be considered for re-biopsy even after radiation therapy.
Since the prevalence was different between the two groups when classified according to the purpose, whether to confirm recurrence or to obtain tissue for mutational analysis, there was a difference in NPV. However, there was no difference in sensitivity or specificity.
In addition, procedure related factors such as the number of aspirations were also similar and there was no need to perform procedures differently.
The re-biopsy by EBUS-TBNA had a better yield than that from the initial diagnosis or staging [25] . This could be a result of choosing the biopsy sites that would give the best results such as the lesions that increased in size or SUV uptake as compared with previous CT and PET-CT images.
The adequacy of the mutation analysis was higher than 90% in this study, which was lower than that seen in previous studies with 100% of diagnostic yield [7, 8] . However, these Korean Cancer Association This article is protected by copyright. All rights reserved. studies are not comparable since a small number of patients were tested with EBUS-TBNA in the previous studies [7, 8] . In addition, mutation analysis was possible in more than 87.5%, regardless of the type of previous treatment in this study and it suggested that tissue sample acquired by EBUS-TBNA was adequate for mutation analysis. The absolute number and proportion of mutation test performed using the re-biopsy samples obtained by EBUS-TBNA actually increased rapidly in clinical practice. The T790M mutation was detected in 25.6% of patients who were previously treated with a TKI agent, and it is lower than the previously reported range of 50 to 60% [26, 27] . The intratumoral heterogeneity might explain the relatively low incidence rate of acquired T790M mutations. The discordance in EGFR mutation was shown between the primary tumor and the metastasis [28, 29] . Spatial T790M heterogeneity was also observed in a study, which performed re-biopsy at multiple sites after TKI treatment [30] . In this study, biopsy was performed on non-progressive lesions in 22 (5.9%) patients, because it was impossible or because the risk of complications was high to approach to the main target with EBUS or TTNA, and EGFR mutation testing were performed in 5 of these patients. In addition, selection bias may also have been a factor, since patients in this study did not include the entire population that underwent re-biopsy after TKI treatment.
In our study, pathological changes were observed in 23 of 283 cases patients (8.1%), though most lesions were suspected to be recurrences of pre-existing tumors seen in CT or PET-CT. Although the number of cases were rather small, it is important to confirm the pathology of a lesion before planning further treatment even if imaging suggests recurrence or disease progression. It also helped clinicians finding the appropriate drug through mutation tests, and treatment plans were changed in 247 of 283 patients (87.3%), based on the EBUS-
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Only 12 patients (3.2%) experienced procedure-related complications which were transient and self-limited. There were no major complications that required intervention for treatment. Though percutaneous re-biopsy showed similar efficacy in patients, it had a post procedural complication rate of 14% (13 of 94 patients) which was higher than that seen with EBUS-TBNA, and required intervention such as chest tube in three patients (23%) [4] .
Because of good diagnostic yield, usefulness for treatment decision and safety, repeated EBUS-TBNA was performed in 8.9% of patients without complications
The strength of our study is that it included diverse group of patients who were treated with radiation therapy and chemotherapy not restricted to surgically treated patients.
Furthermore, we analyzed the data based on the previous therapy. Adequacy, sensitivity, and accuracy were generally acceptable, though prevalence was higher in the chemotherapy group. We also analyzed molecular tests performed by EBUS-TBNA.
Small number of patients with mutation analysis is a limitation of this study, but high adequacy rate of tissues and positivity rates that are consistent with previous studies, suggesting that EBUS-TBNA could be used for tissue acquisition for mutation analysis [31, 32] . Second, measurement of diagnostic yield including true positive, false-positive and false-negative was determined by imaging rather than pathologic confirmation. Because most patients received systemic chemotherapy, radiation or palliative care for recurrence, pathologic confirmation by surgical resection was unavailable [33] . Previous studies for rebiopsy in lung cancer calculated diagnostic yield using similar definition of positivity or negativity [14, 34] . In addition, slowly progressive lesions could be misjudged as true negative, since follow-up duration was 6 months or more. However, the median follow-up duration was 28 months in patients with negative results, and about 70% of patients were followed up for more than 1 year. Therefore, it is unlikely that there were many errors in Korean Cancer Association This article is protected by copyright. All rights reserved.
judgement, although use of the criteria for short follow-up duration at 6 months is a limitation.
Fourth, there exists selection bias, which happened due to choosing target lesion by clinicians' suspicion. However, we clarified object of analysis by including cases suspicious for recurrence or progression compared with previous imaging study. If re-biopsy was done for clinical trial enrollment without evidence of progression, it was excluded. There has been no guideline or criteria for re-biopsy and we intended to investigate the usefulness of rebiopsy using EBUS-TBNA in clinical practice through this study.
In summary, the EBUS-TBNA is a good method for re-biopsy of previously treated lung cancer patients, with a high diagnostic yield. Moreover, the acquired tissue specimens were adequate for mutation analysis. The EBUS-TBNA procedure is not influenced by any lung injury resulted from previous cytotoxic treatments or lung resection. Therefore, besides using for diagnosis of recurrence or progression, re-biopsy by EBUS-TBNA should be considered as a choice of procedure for tissue acquisition in patients with lung cancer.
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